Integrating Network Pharmacology, Molecular Docking and Pharmacological Evaluation for Exploring the
BDNF
CAMP signaling pathway
GC-MS
PC12 cells
corticosterone
Journal
Drug design, development and therapy
ISSN: 1177-8881
Titre abrégé: Drug Des Devel Ther
Pays: New Zealand
ID NLM: 101475745
Informations de publication
Date de publication:
2023
2023
Historique:
received:
14
12
2022
accepted:
12
02
2023
entrez:
16
3
2023
pubmed:
17
3
2023
medline:
21
3
2023
Statut:
epublish
Résumé
To investigate the mechanisms of antidepressant action of active fraction of GC-MS was used to predict chemical compounds, corresponding databases were used to predict chemical compound targets and depression targets, Cytoscape software was used to construct and analyze the protein interaction network map, DAVID database was used to analyze gene ontology (GO) and KEGG signaling pathway, and AGFR software was used to perform molecular docking. Subsequently, the underlying action mechanisms of AFPR on depression predicted by network pharmacology analyses were experimentally validated in a CORT-induced depression model in vitro and in vivo. A total of 52 potential targets of AFPR on antidepressant were obtained. GO is mainly related to chemical synaptic transmission, signal transduction and others. KEGG signaling pathways are mainly related to cAMP signaling pathway and C-type lectin receptor signaling pathway. The experiment results showed that AFPR significantly increased the expression of PRKACA, CREB and BDNF in mouse brain tissue and PC12 cells. Furthermore, after interfered of cAMP in PC12 cells, the decreased expression of PRKACA, CREB and BDNF was reversed by AFPR. AFPR may exert antidepressant effects through multiple components, targets and pathways. Furthermore, it could improve neuroplasticity via the cAMP signaling pathway to improve depression-like symptoms.
Identifiants
pubmed: 36923105
doi: 10.2147/DDDT.S399183
pii: 399183
pmc: PMC10010188
doi:
Substances chimiques
Brain-Derived Neurotrophic Factor
0
Drugs, Chinese Herbal
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
717-735Informations de copyright
© 2023 He et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Cell Death Dis. 2019 Aug 2;10(8):577
pubmed: 31371719
Neurosci Biobehav Rev. 2022 Sep;140:104795
pubmed: 35878793
Neurosci Bull. 2010 Aug;26(4):327-37
pubmed: 20651815
Mol Psychiatry. 2020 Mar;25(3):530-543
pubmed: 31801966
Trends Neurosci. 2015 May;38(5):279-94
pubmed: 25887240
Genes Dev. 2000 Dec 1;14(23):2919-37
pubmed: 11114882
Nat Rev Neurosci. 2013 Jan;14(1):7-23
pubmed: 23254191
Nat Neurosci. 2015 Oct;18(10):1386-93
pubmed: 26404713
J Neurosci. 2020 Feb 12;40(7):1405-1426
pubmed: 31915257
Biol Psychiatry. 2008 Nov 15;64(10):884-90
pubmed: 18675955
JAMA. 2003 Jun 18;289(23):3095-105
pubmed: 12813115
Curr Neuropharmacol. 2016;14(6):610-8
pubmed: 26923778
Biol Psychiatry. 2008 Feb 15;63(4):353-9
pubmed: 17889834
Braz J Psychiatry. 2013;35 Suppl 2:S112-20
pubmed: 24271223
Front Pharmacol. 2019 Oct 09;10:1185
pubmed: 31649545
Cells. 2019 Sep 01;8(9):
pubmed: 31480600
Curr Protoc Neurosci. 2009 Oct;Chapter 9:Unit 9.32
pubmed: 19802817
Cell Physiol Biochem. 2013;31(6):761-77
pubmed: 23735822
Comb Chem High Throughput Screen. 2022 Sep 28;:
pubmed: 36173042
Evid Based Complement Alternat Med. 2014;2014:512081
pubmed: 25525446
J Alzheimers Dis. 2021;80(2):695-713
pubmed: 33579843
Chin Med. 2017 Aug 21;12:23
pubmed: 28835770
Pharmacol Res. 2016 Dec;114:39-41
pubmed: 27720767
Trends Neurosci. 2015 Oct;38(10):637-658
pubmed: 26442697
Int J Mol Sci. 2021 Jun 13;22(12):
pubmed: 34199197
Kidney Blood Press Res. 2018;43(1):220-233
pubmed: 29490297
Brain Res Bull. 2020 Jan;154:51-60
pubmed: 31715311
Annu Rev Neurosci. 2001;24:677-736
pubmed: 11520916
J Tradit Chin Med. 2018 Feb;38(1):12-21
pubmed: 32185947